Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
Reason given in the registry “The study was closed due to the end of funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Aug 2026.
- Ended
- Jul 2026
- Phase
- Phase 2
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT04994808
Withdrawn
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2026.
- Phase
- Phase 2
- Run by
- Memorial Sloan Kettering Cancer Center
- Registry record
- NCT06903702
Terminated
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Reason given in the registry “Slow participant enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2026.
- Ended
- Mar 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06021600
Suspended
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Reason given in the registry “Drugs/Equipment Unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Jul 2026.
- Phase
- Phase 1
- Run by
- Washington University School of Medicine
- Registry record
- NCT05377827
Suspended
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Reason given in the registry “Drugs unavailable”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.
- Phase
- Phase 1
- Run by
- David Wald
- Registry record
- NCT05400122
Terminated
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Reason given in the registry “Funding Sponsor decision due to review of efficacy data from other trials involving investigational product.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.
- Ended
- Jun 2026
- Phase
- Phase 1
- Run by
- Antonio M Jimenez Jimenez
- Registry record
- NCT06158100
Terminated
Lentivirally Redirected CD123 Autologous T Cells in AML
Reason given in the registry “Administrative reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.
- Ended
- Mar 2026
- Phase
- Phase 1
- Run by
- University of Pennsylvania
- Registry record
- NCT03766126
Withdrawn
ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Study withdrawn due to business priority changes”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Jul 2026.
- Phase
- Phase 1
- Run by
- Galecto Biotech AB
- Registry record
- NCT07084584
Terminated
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Reason given in the registry “Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2026.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Registry record
- NCT05716009
Terminated
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Reason given in the registry “Premature withdrawal of investigational product per study sponsor.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2026.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Northwestern University
- Registry record
- NCT05744739
Terminated
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Sponsor's decision”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2026.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Sanofi
- Registry record
- NCT05712278
Terminated
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Reason given in the registry “The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Jun 2026.
- Ended
- Dec 2025
- Run by
- Center for International Blood and Marrow Transplant Research
- Registry record
- NCT05224661
Withdrawn
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Reason given in the registry “Due to corporate strategic adjustment.”
Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2026.
- Phase
- Early phase 1
- Run by
- Guangzhou Bio-gene Technology Co., Ltd
- Registry record
- NCT07123662
Terminated
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given in the registry “No longer a research question to answer.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.
- Ended
- May 2026
- Run by
- Masonic Cancer Center, University of Minnesota
- Registry record
- NCT01962636
Terminated
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given in the registry “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT03246906
Withdrawn
A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia
Reason given in the registry “The test for c-kit was not set up and replaced by NGS MRD”
Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2026.
- Ended
- Nov 2026
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- Registry record
- NCT06116318
Terminated
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Reason given in the registry “Closed for administrative, non-safety-related reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2026.
- Ended
- Jan 2025
- Phase
- Phase 1/2
- Run by
- Sun Pharma Advanced Research Company Limited
- Registry record
- NCT02629692
Withdrawn
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Reason given in the registry “Other - Protocol moved to Withdrawn”
Quoted unchanged from ClinicalTrials.gov; record updated 5 May 2026.
- Phase
- Phase 1
- Run by
- Children's Oncology Group
- Registry record
- NCT07498465
Terminated
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Reason given in the registry “The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2026.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03878199
Terminated
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Reason given in the registry “75% \> Participants”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.
- Ended
- Mar 2025
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT04435691
Terminated
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Reason given in the registry “Patient recruitment problems.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Aurigene Discovery Technologies Limited
- Registry record
- NCT05607199
Terminated
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Adjusted the product development strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Registry record
- NCT05263271
Suspended
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Reason given in the registry “Enrollment on hold pending amendment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.
- Phase
- Phase 1
- Run by
- University of Chicago
- Registry record
- NCT02333162
Terminated
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
Reason given in the registry “Slow/low Enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Inmune Bio, Inc.
- Registry record
- NCT05933070
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Reason given in the registry “Development discontinued”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Mar 2026.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- Shattuck Labs, Inc.
- Registry record
- NCT05275439
Terminated
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Reason given in the registry “Business reasons, not related to safety or efficacy results.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Mar 2026.
- Ended
- Jul 2024
- Phase
- Phase 1
- Run by
- MEI Pharma, Inc.
- Registry record
- NCT03547115
Terminated
Natural Killer-cell Therapy for Acute Myeloid Leukemia
Reason given in the registry “Stop funding”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Mar 2026.
- Ended
- Jan 2026
- Phase
- Phase 1/2
- Run by
- Radboud University Medical Center
- Registry record
- NCT04347616
Suspended
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
Reason given in the registry “Pharmaceutical Company withdrew support and investigational product”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2026.
- Phase
- Phase 1
- Run by
- University of Maryland, Baltimore
- Registry record
- NCT06626633
Terminated
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2026.
- Ended
- Mar 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03404193
Terminated
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Reason given in the registry “Drug supply issues”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2026.
- Ended
- May 2025
- Phase
- Phase 1
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT03772925
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.